Breaking News Instant updates and real-time market news.

TAP

Molson Coors

$60.17

0.06 (0.10%)

, PGR

Progressive

$60.64

-0.97 (-1.57%)

10:33
05/17/18
05/17
10:33
05/17/18
10:33

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Molson Coors (TAP) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying he sees multiple expansion as unlikely because U.S. beer industry volume trends are getting worse, the company's U.S. share trends are not improving, and demographics favor continued pressure on per capita alcohol consumption. 2. Progressive (PGR) downgraded to Market Perform from Outperform at Keefe Bruyette with analyst Meyer Shields citing valuation. 3. CBS (CBS) downgraded to Neutral from Buy at BofA/Merrill with analyst Jessica Reif saying the lawsuit brought by CBS and the special committee alleging a breach of fiduciary duty by the National Amusements Inc. is a significant overhang for shares and will constrain outperformance until a ruling. 4. Canadian National (CNI) downgraded to Neutral on valuation at Macquarie with analyst Konark Gupta citing valuation. 5. Jounce Therapeutics (JNCE) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jim Birchenough saying overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TAP

Molson Coors

$60.17

0.06 (0.10%)

PGR

Progressive

$60.64

-0.97 (-1.57%)

CBS

CBS

$53.47

-0.34 (-0.63%)

CNI

Canadian National

$84.48

1.27 (1.53%)

JNCE

Jounce Therapeutics

$12.19

-5.47 (-30.97%)

  • 18

    May

TAP Molson Coors
$60.17

0.06 (0.10%)

05/03/18
BMOC
05/03/18
NO CHANGE
Target $85
BMOC
Outperform
Molson Coors price target lowered to $85 from $95 at BMO Capital
BMO Capital analyst Amit Sharma lowered his price target on Molson Coors to $85 but kept his Outperform rating. Sharma says that while the "disappointing" quarter deserved a sell-off in the stock, the 15% plunge is overdone considering that the issues with Q1, such as declining U.S. inventories, will reverse.
05/17/18
05/17/18
DOWNGRADE
Target $65

Hold
Stifel downgrades Molson Coors to Hold, sees multiple expansion as unlikely
As previously reported, Stifel analyst Mark Swartzberg downgraded Molson Coors to Hold from Buy, stating that he sees multiple expansion as unlikely because U.S. beer industry volume trends are getting worse, the company's U.S. share trends are not improving, and demographics favor continued pressure on per capita alcohol consumption. He lowered his price target on Molson Coors shares to $65 from $71.
05/16/18
STFL
05/16/18
DOWNGRADE
STFL
Hold
Molson Coors downgraded to Hold from Buy at Stifel
05/03/18
STFL
05/03/18
NO CHANGE
Target $71
STFL
Buy
Molson Coors price target lowered to $71 from $100 at Stifel
Stifel analyst Mark Swartzberg reduced his forecasts for Molson Coors mainly for the U.S. and Europe following the company's Q1 report and reduced his multiple expansion expectations, leading him to lower his price target on the stock to $71 from $100. He maintains a Buy rating on Molson Coors, as he sees the company as highly likely to generate the $1.35B-$1.65B in free cash flow targeted for FY18.
PGR Progressive
$60.64

-0.97 (-1.57%)

01/25/18
WBLR
01/25/18
NO CHANGE
WBLR
Progressive current worries likely overblown, says William Blair
William Blair analyst Adam Klauber attributes the recent weakness in shares of Progressive to cyclical concerns, the California Commissioner's comments on taxes, and also a "blip" in the loss ratio. However, recent data suggest rate increases remain high, and the potential for California to reduce rates materially is small, Klauber tells investors in a research note. The analyst sees limited downside risk in the shares and believes the current worries are likely overblown. Klauber points out that a multiple of 18 times his 2018 operating earnings estimate suggests a stock price of $71, which is nearly 30% above the current price. He keeps an Outperform rating on Progressive.
05/17/18
KBWI
05/17/18
DOWNGRADE
Target $66
KBWI
Market Perform
Progressive downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Meyer Shields downgraded Progressive to Market Perform with an unchanged price target of $66 citing valuation.
05/15/18
WBLR
05/15/18
NO CHANGE
WBLR
Outperform
Progressive shares could top $100 in next 12 months, says William Blair
William Blair analyst Adam Klauber says "rising secular tailwinds" should push Progressive's earnings "materially higher" than expectations. The impact of accelerating bundling should result in the company's earnings per share more than doubling from $2.50 in 2017 to the $5.50 to $6.00 range in 2019, Klauber tells investors in a research note. He notes that the consensus earnings estimate for 2019 is only at $3.97. The benefits of bundling expanding, like higher premium levels and growing invested assets, are just beginning to manifest and do not appear to be reflected in the stock price, the analyst contends. He thinks Progressive shares could reach $100-plus in the next 12 months. The stock closed yesterday at $61.72.
03/27/18
MKMP
03/27/18
NO CHANGE
Target $70
MKMP
Buy
Progressive price target raised to $70 from $65 at MKM Partners
MKM Partners analyst Harry Fong raised his price target on Progressive to $70 after the company's February earnings, noting continued increase in the personal auto policies count and a strong growth in its direct channel of over 14%. Fong adds that the company's auto insurance growth rate is "very impressive" and that the company's underwriting performance is also "excellent". The analyst keeps his Buy rating on Progressive.
CBS CBS
$53.47

-0.34 (-0.63%)

05/15/18
05/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Outperform from Market Perform at Telsey Advisory. 2. CBS (CBS) upgraded to Outperform from Market Perform at Bernstein with the firm saying it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. 3. Ulta Beauty (ULTA) upgraded to Outperform from Perform at Oppenheimer with analyst Rupesh Parikh saying he still sees the potential for more gains and outperformance from current levels. 4. Valeant (VRX) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying he believes the bottom in the stock price has been reached, leading to its usual "counter seasonal trend of outperformance" given that the stock has outperformed the S&P500 from June to January in the past 11 of 15 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
BOFA
05/17/18
DOWNGRADE
BOFA
Neutral
CBS downgraded to Neutral from Buy at BofA/Merrill
05/17/18
05/17/18
DOWNGRADE
Target $58

Neutral
CBS downgraded to Neutral on lawsuit overhang at BofA/Merrill
As previously reported, BofA/Merrill downgraded CBS to Neutral from Buy and cut its price target to $58 from $78. Analyst Jessica Reif said the lawsuit brought by CBS and the special committee alleging a breach of fiduciary duty by the National Amusements Inc. is a significant overhang for shares and will constrain outperformance until a ruling. Further, Reif sees increased risk that CEO Leslie Moonves could leave the company, which would elevate execution risk.
05/17/18
WELS
05/17/18
NO CHANGE
WELS
Market Perform
CBS shares likely return to mid-$60's with no merger, says Wells Fargo
Wells Fargo analyst Marci Ryvicker sees three potential paths unfolding for CBS (CBS) and Viacom (VIAB). The first being CBS remaining a standalone company with Les Moonves in charge. In this scenario the analyst sees CBS shares re-rating to $64, but ultimately being worth $78, and Viacom retreating to $26.50, but being worth $35-$39. The second scenario has CBS and Viacom merging with Moonves in charge. Under this, the new CBS is worth $55 per share with Viacom taken out at $32, Ryvicker tells investors in a research note. Her third scenario has CBS and Viacom merging with Bob Bakish in charge. The analyst values the new CBS at $44 per share in this scenario. At this point, Ryvicker favors a go-it-alone strategy for CBS. She also likes what Bakish is doing at Viacom. The analyst keeps Market Perform rating on both stocks, however, citing the lack of visibility on the outcome or timing.
CNI Canadian National
$84.48

1.27 (1.53%)

05/17/18
05/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the company's transformation should drive "sustainably better growth," which should yield a higher valuation premium. 2. Valero (VLO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Benny Wong saying recent underinvestment in refining, slippages in capacity additions and overdone concerns on long-term demand have set the stage for refining to enter a "golden age" through 2020. 3. ManTech (MANT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso citing valuation. 4. Celanese (CE) upgraded to Buy from Neutral at UBS with analyst John Roberts saying he believes the shares are undervalued and investors do not appreciate the stability and growth in the acetyls chain and the long-term potential in Engineered Materials. 5. Canadian National (CNI) upgraded to Buy from Underperform at BofA/Merrill with analyst Ken Hoexter saying service and volume growth rebounded faster than expected and will only be aided by an improving economy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
MACQ
05/17/18
DOWNGRADE
MACQ
Neutral
Canadian National downgraded to Neutral on valuation at Macquarie
Macquarie analyst Konark Gupta downgraded Canadian National to Neutral from Outperform citing valuation as shares are trading through his unchanged C$106 price target and have significantly outperformed peers since late March.
05/17/18
BOFA
05/17/18
UPGRADE
Target $93
BOFA
Buy
Canadian National upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Ken Hoexter upgraded Canadian National two notches to Buy from Underperform and raised its price target to $93 from $72. Hoexter said service and volume growth rebounded faster than expected and will only be aided by an improving economy. Canadian National continues to make progress towards its increased capital program with short-term locomotive leases and new locomotive orders allowing it to get ahead of volume backlogs, the analyst wrote. Further, Hoexter expects pricing will continue to be above inflation and and the move to add capital will keep it ahead of the curve.
05/15/18
COWN
05/15/18
NO CHANGE
Target $87
COWN
Outperform
Right time to buy Canadian National shares, says Cowen
Cowen analyst Jason Seidl said Canadian National is attacking their network service disruptions through track and yard expansion, new power, additional cars and more people. He believes the company remains well positioned to benefit from improving operations, a strong pricing environment, and solid demand backdrop, making it the right time to buy the shares. Seidl reiterated his Outperform rating and $87 price target on Canadian National.
JNCE Jounce Therapeutics
$12.19

-5.47 (-30.97%)

04/27/18
04/27/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Jounce Therapeutics (JNCE) initiated with a Buy at H.C. Wainwright. 2. Gaia (GAIA) initiated with a Buy at Roth Capital. 3. Inter Pipeline (IPPLF) initiated with a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
WELS
05/17/18
DOWNGRADE
WELS
Market Perform
Jounce Therapeutics downgraded to Market Perform from Outperform at Wells Fargo
05/17/18
HCWC
05/17/18
NO CHANGE
Target $19
HCWC
Buy
Jounce Therapeutics price target lowered to $19 from $33 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Jounce Therapeutics to $19 citing the "limited activity on show" for JTX-2011, either as a monotherapy or when used in combination with Opdivo. With the stock already down today, "a reactionary downgrade here would make little sense," Chattopadhyay tells investors in a research note. He keeps a Buy rating on the shares.
05/17/18
WELS
05/17/18
DOWNGRADE
Target $13
WELS
Market Perform
Wells Fargo downgrades Jounce on 'underwhelming' JTX2011 data
Wells Fargo analyst Jim Birchenough downgraded Jounce Therapeutics to Market Perform from Outperform and cut his price target for the shares to $13 from $37. The stock in premarket trading is down 31%, or $5.43, to $12.24. Overall response rates for JTX-2011 monotherapy in gastric cancer and in triple negative breast cancer, as well as for JTX-2011 plus Opdivo in gastric cancer and in triple negative breast cancer are "underwhelming" and "not competitive with other investigational drugs," Birchenough tells investors in a research note following review of the ASCO abstract. He advises taking a "wait and see approach to assess strength of aggregate data."

TODAY'S FREE FLY STORIES

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change  »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change  »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

MCD

McDonald's

$160.84

1.65 (1.04%)

18:32
09/20/18
09/20
18:32
09/20/18
18:32
Hot Stocks
McDonald's says dividend hike reinforces confidence in long-term targets »

McDonald's says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MCD

McDonald's

$160.84

1.65 (1.04%)

18:31
09/20/18
09/20
18:31
09/20/18
18:31
Hot Stocks
McDonald's raises quarterly dividendy by 15% to $1.16 per share »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

TTPH

Tetraphase

$3.16

0.14 (4.64%)

18:10
09/20/18
09/20
18:10
09/20/18
18:10
Recommendations
Tetraphase analyst commentary  »

Tetraphase's XERAVA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SGH

Smart Global

$30.44

0.7 (2.35%)

18:07
09/20/18
09/20
18:07
09/20/18
18:07
Syndicate
Breaking Syndicate news story on Smart Global »

Smart Global files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 10

    Oct

SGH

Smart Global

$30.44

0.7 (2.35%)

18:07
09/20/18
09/20
18:07
09/20/18
18:07
Syndicate
Breaking Syndicate news story on Smart Global »

Smart Global files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 04

    Oct

  • 10

    Oct

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

17:46
09/20/18
09/20
17:46
09/20/18
17:46
Recommendations
Pier 1 Imports analyst commentary at Loop Capital »

Pier 1 Imports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$46.06

1.01 (2.24%)

17:43
09/20/18
09/20
17:43
09/20/18
17:43
Hot Stocks
Breaking Hot Stocks news story on Micron »

Micron reverses, now down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

ACXM

Acxiom

$50.28

2.09 (4.34%)

, IPG

Interpublic Group

$22.68

0.315 (1.41%)

17:41
09/20/18
09/20
17:41
09/20/18
17:41
Hot Stocks
Acxiom shareholders approve AMS sale, will switch name to LiveRamp after close »

Acxiom (ACXM) announced…

ACXM

Acxiom

$50.28

2.09 (4.34%)

IPG

Interpublic Group

$22.68

0.315 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

IPCI

Intellipharmaceutics

$2.92

0.15 (5.42%)

17:39
09/20/18
09/20
17:39
09/20/18
17:39
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$301.53

-10.71 (-3.43%)

17:30
09/20/18
09/20
17:30
09/20/18
17:30
Hot Stocks
Northrop Grumman completes first qualification test of rocket motor in Atlas V »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUM

Yum! Brands

$88.96

0.39 (0.44%)

17:28
09/20/18
09/20
17:28
09/20/18
17:28
Recommendations
Yum! Brands analyst commentary at Tigress Financial »

Yum! Brands continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

17:25
09/20/18
09/20
17:25
09/20/18
17:25
Conference/Events
SEC to hold an investor roundtable »

Investor Roundtable to…

FSCT

ForeScout

$39.56

1.2 (3.13%)

17:24
09/20/18
09/20
17:24
09/20/18
17:24
Hot Stocks
ForeScout beneficial owner Amadeus Capital Partners sells $4.6M in shares »

ForeScout beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

MU

Micron

$46.06

1.01 (2.24%)

17:23
09/20/18
09/20
17:23
09/20/18
17:23
Hot Stocks
Micron says it is seeing CPU shortage »

Says confident of long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.